⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Aurion Biotech and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Aurion Biotech
↗Seattle, USA
Aurion Biotech is a clinical-stage biotechnology company dedicated to developing and commercializing regenerative therapies to restore vision. The company focuses on treating corneal endothelial diseases, such as corneal edema and bullous keratopathy, using a proprietary allogeneic cell therapy platform that aims to eliminate the need for traditional donor corneal transplants.
In March 2025, Alcon acquired a majority interest in Aurion Biotech, positioning the company to leverage Alcon's global scale while maintaining its status as a separate operating entity. The company's lead asset, AURN001, has received FDA Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Ophthalmology / Cell Therapy
SIZE & FINANCIALS
Employees:51-200
Founded:2020
Ownership:subsidiary
Status:operating
FUNDING
Stage:Series C
Total Raised:$120M
Investors:Alcon, Deerfield Management, Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision (KKR), Visionary Ventures
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Cell therapy
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Alcon
Acquired By:Alcon (2025-03-01)
Key Partnerships:Alcon (Majority Owner), Kyoto Prefectural University of Medicine (Technology Originator)
COMPETITION
Position:Leader
Competitors:Emmecell, Cloudbreak Pharma
LEADERSHIP
Key Executives:
Arnaud Lacoste - CEO
Scientific Founders:Professor Shigeru Kinoshita
LINKS
Website:aurionbiotech.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Aurion Biotech. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.